Prof Dr. Nives Pećina-Šlaus – Cancer Genetics – Best Researcher Award

Posted on 29/04/202429/04/2024 by Pencis

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cells—Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue “Advances in Molecular Genetics of Brain Tumors”. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)

Prof Dr. Zsuzsanna Suba – Cancer Genetics – Distinguished Cancer Treatment Innovation Award

Posted on 29/04/202429/04/2024 by Pencis

Prof Dr. Zsuzsanna Suba - Cancer Genetics - Distinguished Cancer Treatment Innovation Award

National Institute of Oncology, Budapest - Hungary

AUTHOR PROFILE

Orcid

EARLY ACADEMIC PURSUITS

Prof. Dr. Zsuzsanna Suba began her academic journey at Semmelweis University in Budapest, where she earned both MD and PhD degrees. During this time, she also obtained postdoctoral board certification in pathology, laying the foundation for her expertise in cancer research.

PROFESSIONAL ENDEAVORS

After completing her postdoctoral certification, Suba delved into cancer research, initially focusing on the effects of chemotherapeutic agents on cell cultures and experimental animals. Later, she expanded her expertise by gaining scientific graduations in oral pathology and habilitation at the Institute of Oral and Maxillofacial Surgery, Semmelweis University, as well as a certification in oral pathology from the University of Sheffield.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Suba's research has been multifaceted, covering various aspects of cancer development and therapy response. She led a working group that investigated the osseointegration of biomaterials in oral and periodontal tissues and explored metabolic and hormonal aspects of oral cancer. Notably, her research identified insulin resistance and estrogen deficiency as risk factors for oral cancer.At the National Institute of Oncology in Budapest, Suba delved into the correlations among hormonal imbalance, metabolic disorders, and genomic instability in female breast cancer patients.

IMPACT AND INFLUENCE

Suba's work has significantly contributed to our understanding of cancer development and treatment response, particularly in oral and breast cancer. Her identification of novel risk factors and exploration of hormonal and metabolic influences have informed both clinical practice and further research in the field.

ACADEMIC CITATIONS

Suba's contributions to cancer research have garnered recognition and citations within the academic community, solidifying her reputation as an expert in clinical cancer genetics and pathology.

LEGACY AND FUTURE CONTRIBUTIONS

As a professor emeritus, Suba continues to shape the future of cancer research, advocating for new strategies that prioritize DNA stabilization in cancer cases. Her emphasis on supportive cancer care underscores the importance of innovative approaches to enhance patient outcomes and quality of life.

NOTABLE PUBLICATIONS

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care. 2024

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 (7)

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Posted on 06/04/202406/04/2024 by Pencis

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Prof. Paolo De Simone – Oncology Therapy – Most Liked Article Award

Posted on 30/03/202430/03/2024 by Pencis

Prof. Paolo De Simone - Oncology Therapy - Most Liked Article Award

UNIVERSITY OF PISA - Italy

Author Profile

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Paolo De Simone graduated summa cum laude in Medicine and Surgery from the University of Rome La Sapienza. His thesis was titled "Laparoscopic cholecystectomy in the treatment of gallstone lithiasis: prospective analysis of the results of our experience" under the supervision of Prof. Raffaello Cortesini.He earned his Specialist Diploma in General Surgery summa cum laude from the University of Rome “La Sapienza”. His thesis focused on "The role of laparoscopic surgery in the treatment of benign and malignant gastric pathologies" under the guidance of Prof. Raffaello Cortesini.Paolo De Simone achieved his PhD summa cum laude in Surgical Pathophysiology.

PROFESSIONAL ENDEAVORS

Registered in the Order of Doctors-Surgeons and Dentists of the Province of Rome with registration number 46702. He also qualified to practice the medical-surgical profession at the University of Rome “La Sapienza”. He served as a Foreign Resident-Assistant at the General Surgery Service of CHU André Vésale, Université Libre de Bruxelles, Montigny-Le-Tilleul, Belgium, and at the Thoracic and Vascular Surgery Service of the Hospital Avicenne, Bobigny, France. Paolo De Simone held several medical director positions:General Surgery Unit, Civil Hospital of Vittorio Veneto (TV),Organ Transplant Unit, San Salvatore Civil Hospital, L'Aquila,Service de Chirurgie Digestive, Hopital Erasme, Université Libre de Bruxelles, Brussels,University Liver Transplantology Unit, Pisa University Hospital.Currently, he is an Associate Professor of Surgery at the University of Pisa. He was elected Director of the School of Specialization in Surgery of the Digestive System and serves as Director of the Liver Surgery and Liver Transplant Unit, AOUP.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPY

Appointed as the Coordinator of the regional liver transplant program by DGRT of 17 December 2018, n. 1450. He also managed clinical, scientific, and educational coordination of terminal liver failure and liver transplantation (DG AOUP Resolution 852 of 09/20/2023).His research has covered areas like laparoscopic cholecystectomy, treatment of benign and malignant gastric pathologies, and liver transplantology.

IMPACT AND INFLUENCE

As Coordinator of the Liver Transplant Program of the Tuscany Region, he has significantly contributed to the advancement of liver transplantation in the region.

LEGACY AND FUTURE CONTRIBUTIONS

Paolo De Simone's legacy lies in his extensive contributions to the fields of general surgery, liver surgery, and liver transplantology. His future contributions are anticipated in enhancing liver transplant programs, furthering research in surgical pathophysiology, and mentoring the next generation of surgeons through his academic roles.

NOTABLE PUBLICATIONS

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.

First-in-human liver transplantation from a centenarian deceased donor after brain death.

Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation.

An Unexpected Case of Opisthorchis felineus Infection Revealed during Liver Transplantation.

An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.

Dr. Francesco Raspagliesi – Gynecologic Oncology – Best Researcher Award

Posted on 27/03/202427/03/2024 by Pencis

Dr. Francesco Raspagliesi - Gynecologic Oncology - Best Researcher Award

Fondazione IRCCS Istituto nazionale Tumori di Milano - Italy

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Francesco Raspagliesi began his academic journey with a Degree in Medicine and Surgery from the University of Catania, Italy, which he completed on March 7, 1981. Following this foundational education, he obtained qualifications to practice medicine in 1981 and specialized in Obstetrics and Gynecology from the University of Catania in 1985 and 1988. These early academic pursuits laid the groundwork for his future professional endeavors in the field of gynecologic oncology.

PROFESSIONAL ENDEAVORS

From 1985 to 1992, Raspagliesi served as a Research Fellow at the Fondazione IRCCS Istituto Nazionale Tumori di Milano. He continued his professional growth at the same institution, becoming a Dirigente Medico di 1° Livello from 1992 to 1999 and advancing to Dirigente Medico di 2° Livello Gynecologic Oncology Unit Director from 1999 to 2019. His long-standing association with the Fondazione IRCCS Istituto Nazionale Tumori di Milano demonstrates his commitment and dedication to the field of gynecologic oncology and patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON GYNECOLOGIC ONCOLOGY

Throughout his career, Raspagliesi has made significant contributions to the field of Obstetrics and Gynecology. His research and clinical work have focused on gynecologic oncology, particularly in the treatment and management of gynecologic cancers. His expertise and leadership as the Gynecologic Oncology Unit Director have contributed to advancements in the diagnosis, treatment, and care of patients with gynecologic cancers.

IMPACT AND INFLUENCE

As a respected figure in the field of gynecologic oncology, Raspagliesi's work has had a profound impact on patient care, research, and education. His leadership roles and contributions to research have helped shape the way gynecologic cancers are treated and managed, influencing clinical practice and improving patient outcomes.

LEGACY AND FUTURE CONTRIBUTIONS

Francesco Raspagliesi's legacy in the field of Obstetrics and Gynecology is characterized by his dedication to patient care, leadership in gynecologic oncology, and contributions to research and education. His continued commitment to advancing the field through research, mentorship, and clinical practice ensures that his influence will be felt by future generations of gynecologic oncologists.

NOTABLE PUBLICATIONS

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group. 2024

Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes. 2024

Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs. 2024

Impact of Cold Ischemia on the Stability of ¹H-MRS-Detected Metabolic Profiles of Ovarian Cancer Specimens. 2024

Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? (2) 2024

Prof. Apostolos Zaravinos – Cancer Genetics – Excellence in Research

Posted on 25/03/202425/03/2024 by Pencis

Prof. Apostolos Zaravinos - Cancer Genetics - Excellence in Research

European University Cyprus - Cyprus

Author Profile

Google Scholar

Orcid

Scopus

EARLY ACADEMIC PURSUITS

Dr. Apostolos Zaravinos began his academic journey with a B.Sc. in Molecular Biology from the Department of Biology at the University of Crete in 2004. He further pursued his passion for medicine by obtaining his Ph.D. in Medicine from the Medical School of the same university in 2008. These foundational academic pursuits laid the groundwork for his subsequent research and professional endeavors in the field of cancer genetics and molecular biology.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Dr. Zaravinos embarked on a series of professional roles that enriched his expertise and contributed to the scientific community. He worked as a Research Scientist at the Harris Birthright Research Center for Fetal Medicine at King’s College Hospital from 2009 to 2010. Subsequently, he performed postdoctoral research in Cancer Genetics at the Molecular Medicine Research Center of the University of Cyprus from 2011 to 2013. He further honed his skills in Immunogenetics and Cancer Genetics during his postdoctoral training at the Department of Laboratory Medicine of the Karolinska Institute from 2013 to 2015.In 2015, Dr. Zaravinos was appointed as an Assistant Professor of Cancer Genetics at the European University Cyprus. He was promoted to the rank of Associate Professor in 2019. He also served as an Associate Professor of Genetics at the Department of Basic Medical Science, College of Medicine (CMED) at Qatar University from 2020 to 2021. These academic positions allowed him to mentor students, lead research projects, and contribute to the advancement of cancer genetics and immunogenetics.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Dr. Zaravinos' research contributions are significant and multifaceted. His primary research aim is to achieve an advanced understanding of carcinogenesis by investigating interactions between genes. He is particularly interested in Cancer Immunogenetics and aims to elucidate how the tumor microenvironment relates to different aspects of tumor biology. His research has focused on examining the immune landscape of inflamed tumors, including colorectal cancer and skin melanoma, using next-generation sequencing approaches.

IMPACT AND INFLUENCE

Dr. Zaravinos has made a substantial impact on the field of cancer genetics and immunogenetics. He has authored over 125 original research articles and 7 book chapters, demonstrating his prolific research output. His work has been cited over 3,600 times, with an h-index of 35, as documented on Scopus. His research findings have contributed to the scientific community's understanding of carcinogenesis, tumor immunology, and the tumor microenvironment.

ACADEMIC CITES

Dr. Zaravinos' research has garnered significant attention and recognition in the scientific community, as evidenced by his high citation count and h-index. His publications have been cited over 3,600 times, highlighting the impact and relevance of his research in the field of cancer genetics and immunogenetics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zaravinos' legacy in the field of cancer genetics and immunogenetics is characterized by his groundbreaking research, mentorship, and contributions to scientific literature. His work has paved the way for future research endeavors aimed at understanding carcinogenesis, tumor immunology, and the tumor microenvironment. As a dedicated researcher and educator, Dr. Zaravinos continues to inspire and influence the next generation of scientists, leaving a lasting impact on the field of cancer genetics and molecular biology. His future contributions are eagerly anticipated as he continues to explore new avenues in cancer research and mentor emerging scientists in the field.

NOTABLE PUBLICATIONS

Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. 2024

Peptide absent sequences emerging in human cancers. 2024

Immune Cytolytic Activity and Strategies for Therapeutic Treatment. 2024

Strand asymmetries across genomic processes. 2023

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. 2023 (3)

Aya H. Soliman – Tumor Immunology – Best Researcher Award

Posted on 03/01/202428/02/2024 by Pencis

Ms.Aya H. Soliman - Tumor Immunology - Best Researcher Award

German University in Cairo - Egypt

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Aya H. Soliman's academic journey commenced with a fervent pursuit of knowledge. Her early years were marked by a dedication to learning, demonstrating an insatiable curiosity and a penchant for academic excellence. Whether it be notable achievements, academic milestones, or early influences, this period laid the foundation for her future endeavors.

PROFESSIONAL ENDEAVORS:

Embarking on a path of professional growth, Soliman transitioned seamlessly from academia to the professional realm. Her career trajectory reflects a commitment to applying theoretical knowledge to real-world challenges. A closer examination of her professional undertakings unveils a strategic and purposeful approach to making significant contributions in her chosen field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Soliman's contributions to her field are nothing short of groundbreaking. Her research focus is characterized by a meticulous exploration of pertinent issues, coupled with innovative methodologies. By delving into specific themes, she has enriched the academic landscape with fresh perspectives and novel insights, leaving an indelible mark on her area of expertise.

IMPACT AND INFLUENCE:

The impact of Soliman's work extends far beyond the confines of academia. Her research and professional activities have influenced not only fellow scholars but also practitioners in the field. By contributing to the advancement of knowledge, she has played a pivotal role in shaping industry practices and policies, showcasing a far-reaching influence.

ACADEMIC CITES:

A quantitative measure of Soliman's academic influence lies in the citation of her work. The number of times her research has been referenced underscores its significance within scholarly discourse. Her contributions have become integral to the academic canon, with citations serving as a testament to the enduring relevance of her ideas.

FUTURE CONTRIBUTIONS:

Looking ahead, Soliman's future contributions hold promise for continued innovation and advancement. Anticipating the evolving landscape of her field, she remains poised to address emerging challenges and contribute novel solutions. The trajectory of her future contributions is eagerly awaited, promising to shape the direction of academic and professional discourse.

Notable Publications

Medical Oncology

Posted on 07/10/202313/10/2023 by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.